CLChuan Li

Chuan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chuan Li has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Interpretable machine learning leverages proteomics to improve cardiovascular disease risk prediction and biomarker identification

    by Héctor Climente-González, Min Oh, Urszula Chajewska, Roya Hosseini, Sudipto Mukherjee, Wei Gan, Matthew Traylor, Sile Hu, Ghazaleh Fatemifar, Jonas Ghouse, et al.

    Background Cardiovascular diseases (CVDs) rank amongst the leading causes of long-term disability and mortality. Predicting CVD risk and identifying associated genes are crucial for prevention, early intervention, and drug discovery. The recent availability of UK Biobank Proteomics data enables investigation of blood proteins and their association with a variety of diseases. We sought to predict 10 year CVD risk using this data modality and known CVD risk factors. Methods We focused on the UK Biobank participants that were included in the UK Biobank Pharma Proteomics Project. After applying exclusions, 50,057 participants were included, aged 40–69 years at recruitment. We employed the Explainable Boosting Machine (EBM), an interpretable machine learning model, to predict the 10 year risk of primary coronary artery disease, ischemic stroke or myocardial infarction. The model had access to 2978 features (2923 proteins and 55 risk factors). Model performance was evaluated using 10-fold cross-validation. Results The EBM model using proteomics outperforms equation-based risk scores such as PREVENT, with a receiver operating characteristic curve (AUROC) of 0.767 and an area under the precision-recall curve (AUPRC) of 0.241; adding clinical features improves these figures to 0.785 and 0.284, respectively. Our models demonstrate consistent performance across sexes and ethnicities and provide insights into individualized disease risk predictions and underlying disease biology. Conclusions In conclusion, we present a more accurate and explanatory framework for proteomics data analysis, supporting future approaches that prioritize individualized disease risk prediction, and identification of target genes for drug development.


  • Open Access

    Further Evidence for Strong Nonneutrality of Yeast Synonymous Mutations

    by Xukang Shen, Siliang Song, Chuan Li, Jianzhi Zhang

    Although synonymous mutations are commonly assumed neutral or nearly so, recent years have seen reports of fitness effects of synonymous mutations detected under laboratory conditions. In a previous study, we used genome editing to construct thousands of yeast mutants each carrying a synonymous or nonsynonymous mutation in one of 21 genes, and discovered that most synonymous and most nonsynonymous mutations are deleterious. A concern was raised that this observation could be caused by the fitness effects of potential CRISPR/Cas9 off-target edits and/or secondary mutations, and an experiment that would be refractory to such effects was proposed. Using genome sequencing, we here show that no CRISPR/Cas9 off-target editing occurred, although some mutants did carry secondary mutations. Analysis of mutants with negligible effects from secondary mutations and new data collected from the proposed experiment confirms the original conclusion. These findings, along with other reports of fitness effects of synonymous mutations from both case and systematic studies, necessitate a paradigm shift from assuming (near) neutrality of synonymous mutations.


  • Open Access

    Interpretable Machine Learning Leverages Proteomics to Improve Cardiovascular Disease Risk Prediction and Biomarker Identification

    by Héctor Climente-González, Min Oh, Urszula Chajewska, Roya Hosseini, Sudipto Mukherjee, Wei Gan, Matthew Traylor, Sile Hu, Ghazaleh Fatemifar, Paul Pangilinan Del Villar, et al.

    Cardiovascular diseases (CVD), primarily coronary heart disease and stroke, rank amongst the leading causes of long-term disability and mortality. Providing accurate disease risk predictions and identifying genes associated with CVD are crucial for prevention, early intervention, and the development of novel medications. The recent availability of UK Biobank Proteomics data enables the investigation of the blood proteome and its association with a wide variety of diseases. We employed the Explainable Boosting Machine (EBM), an interpretable machine learning model, for CVD risk prediction. The EBM model using proteomics outperforms traditional clinical models with an AUROC of 0.767 and an AUPRC of 0.2405. Adding clinical features further improves the AUROC to 0.785 and the AUPRC to 0.2835. Our models demonstrate consistent performance across sexes and ethnicities. While most prior studies using proteomics data for disease prediction have primarily focused on maximizing the accuracy at the population level, our model provides additional enriched insights into individualized disease risk predictions and in-depth biological insights into biomarkers. Our analysis also uncovers nonlinear risks linked to varying feature values. We further corroborate our findings using statistical approaches and evidence from the literature. In conclusion, we present a highly accurate and explanatory framework for proteomics data analysis, offering comprehensive and in-depth molecular and clinical insights. Our findings support future approaches that prioritize individualized disease risk prediction and the identification of target genes for drug development.


  • Open Access

    Data from An LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation

    by Christopher W. Murray, Jennifer J. Brady, Min K. Tsai, Chuan Li, Ian P. Winters, Rui Tang, Laura Andrejka, Rosanna K. Ma, Christian A. Kunder, Pauline Chu, et al.

    The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood. To investigate the tumor-suppressive capacity of four canonical families of LKB1 substrates in vivo, we used CRISPR/Cas9-mediated combinatorial genome editing in a mouse model of oncogenic KRAS-driven lung adenocarcinoma. We demonstrate that members of the SIK family are critical for constraining tumor development. Histologic and gene-expression similarities between LKB1- and SIK-deficient tumors suggest that SIKs and LKB1 operate within the same axis. Furthermore, a gene-expression signature reflecting SIK deficiency is enriched in LKB1-mutant human lung adenocarcinomas and is regulated by LKB1 in human cancer cell lines. Together, these findings reveal a key LKB1–SIK tumor-suppressive axis and underscore the need to redirect efforts to elucidate the mechanisms through which LKB1 mediates tumor suppression.Significance:Uncovering the effectors of frequently altered tumor suppressor genes is critical for understanding the fundamental driving forces of cancer growth. Our identification of the SIK family of kinases as effectors of LKB1-mediated tumor suppression will refocus future mechanistic studies and may lead to new avenues for genotype-specific therapeutic interventions.This article is highlighted in the In This Issue feature, p. 1469

  • Open Access

    Data from An LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation

    by Christopher W. Murray, Jennifer J. Brady, Min K. Tsai, Chuan Li, Ian P. Winters, Rui Tang, Laura Andrejka, Rosanna K. Ma, Christian A. Kunder, Pauline Chu, et al.

    The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood. To investigate the tumor-suppressive capacity of four canonical families of LKB1 substrates in vivo, we used CRISPR/Cas9-mediated combinatorial genome editing in a mouse model of oncogenic KRAS-driven lung adenocarcinoma. We demonstrate that members of the SIK family are critical for constraining tumor development. Histologic and gene-expression similarities between LKB1- and SIK-deficient tumors suggest that SIKs and LKB1 operate within the same axis. Furthermore, a gene-expression signature reflecting SIK deficiency is enriched in LKB1-mutant human lung adenocarcinomas and is regulated by LKB1 in human cancer cell lines. Together, these findings reveal a key LKB1–SIK tumor-suppressive axis and underscore the need to redirect efforts to elucidate the mechanisms through which LKB1 mediates tumor suppression.Significance:Uncovering the effectors of frequently altered tumor suppressor genes is critical for understanding the fundamental driving forces of cancer growth. Our identification of the SIK family of kinases as effectors of LKB1-mediated tumor suppression will refocus future mechanistic studies and may lead to new avenues for genotype-specific therapeutic interventions.This article is highlighted in the In This Issue feature, p. 1469

  • Open Access

    Supplementary Figures S1-S3 from Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

    by Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka, et al.

  • Open Access

    Supplementary Figures S8-S10 from Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

    by Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka, et al.

  • Open Access

    Table S2 from A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer

    by Hongchen Cai, Su Kit Chew, Chuan Li, Min K. Tsai, Laura Andrejka, Christopher W. Murray, Nicholas W. Hughes, Emily G. Shuldiner, Emily L. Ashkin, Rui Tang, et al.

    Table S2. The information of sgRNA vectors in the high content Lenti-sgTS102/Cre pool.

  • Open Access

    Data from A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer

    by Hongchen Cai, Su Kit Chew, Chuan Li, Min K. Tsai, Laura Andrejka, Christopher W. Murray, Nicholas W. Hughes, Emily G. Shuldiner, Emily L. Ashkin, Rui Tang, et al.

    Cancer genotyping has identified a large number of putative tumor suppressor genes. Carcinogenesis is a multistep process, but the importance and specific roles of many of these genes during tumor initiation, growth, and progression remain unknown. Here we use a multiplexed mouse model of oncogenic KRAS–driven lung cancer to quantify the impact of 48 known and putative tumor suppressor genes on diverse aspects of carcinogenesis at an unprecedented scale and resolution. We uncover many previously understudied functional tumor suppressors that constrain cancer in vivo. Inactivation of some genes substantially increased growth, whereas the inactivation of others increases tumor initiation and/or the emergence of exceptionally large tumors. These functional in vivo analyses revealed an unexpectedly complex landscape of tumor suppression that has implications for understanding cancer evolution, interpreting clinical cancer genome sequencing data, and directing approaches to limit tumor initiation and progression.Significance:Our high-throughput and high-resolution analysis of tumor suppression uncovered novel genetic determinants of oncogenic KRAS–driven lung cancer initiation, overall growth, and exceptional growth. This taxonomy is consistent with changing constraints during the life history of cancer and highlights the value of quantitative in vivo genetic analyses in autochthonous cancer models.This article is highlighted in the In This Issue feature, p. 1601

  • Open Access

    Data from Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

    by Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka, et al.

    In lung adenocarcinoma, oncogenic EGFR mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth and response to therapy in vivo remains largely unknown. By quantifying the effects of inactivating 10 putative tumor suppressor genes in a mouse model of EGFR-driven Trp53-deficient lung adenocarcinoma, we found that Apc, Rb1, or Rbm10 inactivation strongly promoted tumor growth. Unexpectedly, inactivation of Lkb1 or Setd2—the strongest drivers of growth in a KRAS-driven model—reduced EGFR-driven tumor growth. These results are consistent with mutational frequencies in human EGFR- and KRAS-driven lung adenocarcinomas. Furthermore, KEAP1 inactivation reduced the sensitivity of EGFR-driven tumors to the EGFR inhibitor osimertinib, and mutations in genes in the KEAP1 pathway were associated with decreased time on tyrosine kinase inhibitor treatment in patients. Our study highlights how the impact of genetic alterations differs across oncogenic contexts and that the fitness landscape shifts upon treatment.Significance:By modeling complex genotypes in vivo, this study reveals key tumor suppressors that constrain the growth of EGFR-mutant tumors. Furthermore, we uncovered that KEAP1 inactivation reduces the sensitivity of these tumors to tyrosine kinase inhibitors. Thus, our approach identifies genotypes of biological and therapeutic importance in this disease.This article is highlighted in the In This Issue feature, p. 1601